Lantheus to acquire oncology company Progenics Pharmaceuticals

This article was originally published here

As per terms of the deal, Progenics shareholders will secure 0.2502 shares of Lantheus stock for each share of Progenics stock, representing around 35% aggregate ownership interest in

The post Lantheus to acquire oncology company Progenics Pharmaceuticals appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply